Aspire Biopharma, Inc. (NASDAQ:PWUP) | WebDisclosure

Basculer en Français

10165	Companies
208917	Keywords
138987	Articles
110720	Press releases

Headlines Articles Press releases Aspire Biopharma, Inc.

Home
Companies
Aspire Biopharma, Inc.

PRESS RELEASE

published on 06/10/2025 at 14:30, 9 months 26 days ago

Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer
Michael Howe to become CEO of Aspire Biopharma Holdings, Inc. on June 10, 2025. His extensive career in leading brands and early-stage companies makes him a strategic fit for the role

Healthcare Board Member CEO Michael Howe Aspire Biopharma Holdings, Inc.
BRIEF

published on 05/28/2025 at 14:35, 10 months 9 days ago

Aspire Biopharma dévoile BUZZ BOMB™ : une nouvelle ère dans les compléments pré-entraînement

Technologie Sublinguale Marché Du Fitness Supplément Pré-entraînement BUZZ BOMB™ Livraison De Caféine
BRIEF

published on 05/28/2025 at 14:35, 10 months 9 days ago

Aspire Biopharma Unveils BUZZ BOMB™: A New Era in Pre-Workout Supplements

Sublingual Technology Fitness Market Pre-workout Supplement BUZZ BOMB™ Caffeine Delivery
PRESS RELEASE

published on 05/28/2025 at 14:30, 10 months 9 days ago

Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025
Aspire Biopharma introduces BUZZ BOMB™, a sublingual pre-workout supplement delivering rapid caffeine to support athletes' performance. Six flavors available in convenient single servings. Global pre-workout supplements market on the rise

Aspire Biopharma Pre-workout Supplement Sublingual BUZZ BOMB™ Caffeine
BRIEF

published on 05/20/2025 at 14:35, 10 months 17 days ago

Aspire Biopharma lance un essai de phase 1 sur une formulation d'aspirine à haute dose

Développement Clinique Examen De La FDA Essai De Phase 1 Aspirine À Haute Dose Absorption Sublinguale
BRIEF

published on 05/20/2025 at 14:35, 10 months 17 days ago

Aspire Biopharma Begins Phase 1 Trial of High-Dose Aspirin Formulation

Clinical Development Phase 1 Trial FDA Review High-dose Aspirin Sublingual Absorption
PRESS RELEASE

published on 05/20/2025 at 14:30, 10 months 17 days ago

Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
Aspire Biopharma initiates Phase 1 trial for high-dose aspirin formulation in the United States, targeting accelerated approval with positive data anticipated in 3Q 2025

Accelerated Approval Phase 1 Trial FDA Feedback Aspire Biopharma High-dose Aspirin Formulation
BRIEF

published on 05/08/2025 at 14:05, 10 months 29 days ago

Aspire Biopharma to Participate in Sidoti Virtual Investor Conference

Investor Presentation Drug Delivery Technology Sidoti Conference Aspire Biopharma Virtual Meetings
BRIEF

published on 05/08/2025 at 14:05, 10 months 29 days ago

Aspire Biopharma participera à la conférence virtuelle des investisseurs de Sidoti

Presentation Aux Investisseurs Technologie D'administration De Médicaments Conférence De Sidoti Aspire Biopharma Réunions Virtuelles
PRESS RELEASE

published on 05/08/2025 at 14:00, 10 months 29 days ago

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21
Aspire Biopharma to present at Sidoti Virtual Investor Conference on May 21 and host virtual one-on-ones with investors. Company's disruptive drug delivery technology highlighted

Sidoti Virtual Investor Conference Virtual Presentation One-on-one Meetings Drug Delivery Technology Aspire Biopharma

Accesswire

Published on 04/07/2026 at 12:00, 4 minutes ago

Banyan Gold Continues to Intersect High-Grade Gold in Powerline, AurMac Deposit, Yukon, Canada
Published on 04/07/2026 at 09:30, 2 hours 34 minutes ago

Formation Metals to Host Live Investor Webinar on the N2 Gold Project to Discuss Phase 1 Drill Results, including 1.75 g/t Au over 30.4 Metres, and Maiden Resource Estimate Following Fully Funded 30,000-Metre Program
Published on 04/07/2026 at 09:05, 2 hours 59 minutes ago

BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries
Published on 04/07/2026 at 09:01, 3 hours 3 minutes ago

Apex Drills 81.6 m of 2.02% REO, including 50.9 m of 2.40% REO, Extending Strike Length of Main Body, with Highly Enriched NdPr Zone at Rift
Published on 04/07/2026 at 08:00, 4 hours 4 minutes ago

Caledonia Mining Corporation Plc: Encouraging Results From Deep Level Drilling at Blanket Mine

View all ACCESSWIRE

EQS Group

Published on 04/07/2026 at 11:50, 14 minutes ago

4finance announces early redemption of its EUR Notes due October 2026
Published on 04/07/2026 at 11:46, 18 minutes ago

POS-Transaction in Own Shares
Published on 04/07/2026 at 11:06, 57 minutes ago

TenneT Germany completes inaugural ratings process and prepares for debt capital market debut
Published on 04/07/2026 at 10:58, 1 hour 6 minutes ago

Original-Research: Daldrup & Söhne (von Quirin Privatbank Kapitalmarktgeschäft): Buy
Published on 04/07/2026 at 10:05, 1 hour 59 minutes ago

Ye celebrates his birthday on June 8 with a show at GelreDome; free bus transport arranged for fans from Germany

Les Echos

Published on 04/07/2026 at 12:00, 4 minutes ago

Disclosure of shares outstanding and voting rights - 07.04.2026
Published on 04/07/2026 at 12:00, 4 minutes ago

Déclaration nombre d'actions et droits de vote - 07.04.2026
Published on 04/07/2026 at 08:30, 3 hours 34 minutes ago

Edenred achieves CDP “A” rating and joins the ranks of global leaders in climate action
Published on 04/07/2026 at 08:30, 3 hours 34 minutes ago

Edenred obtient la note « A » au CDP et rejoint les leaders mondiaux engagés pour le climat
Published on 04/07/2026 at 08:00, 4 hours 4 minutes ago

Global Agreement Announced at G7 One Health Summit to Accelerate Access to Diagnostics and Responses to Rising Health Threats

View all LES ECHOS COMFI WIRE